N🟁N

Salix Pharmaceuticals to Present at Piper Jaffray Conference

  //health-fitness.news-articles.net/content/2010/ .. cals-to-present-at-piper-jaffray-conference.html
  Published in Health and Fitness on Tuesday, November 23rd 2010 at 4:05 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

RALEIGH, N.C.--([ BUSINESS WIRE ])--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Piper Jaffray 22^nd Annual Healthcare Conference in New York, NY on Tuesday, November 30 at 11:00 a.m. ET.

Interested parties can access a live audio web cast of the presentation at [ http://www.salix.com ]. A replay of the presentation will be available at the same location.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salixa™s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Companya™s gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN^® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP^® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP^® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets,), VISICOL^® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISOa" (mesalamine) extended-release capsules 0.375 g., METOZOLV^® ODT (metoclopramide HCl), PEPCID^® (famotidine) for Oral Suspension, Oral Suspension DIURIL^® (Chlorothiazide), AZASAN^® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC^® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC^® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT^® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT^® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, crofelemer and rifaximin for additional indications are under development.

For full prescribing information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, on Salix products, please visit [ www.salix.com ] or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol aSLXP.a

For more information please visit our web site at [ www.salix.com ]. Information on our web site is not incorporated in our SEC filings.